Ann: Positive preliminary results from ATL1102 DMD Phase II trial, page-445

Yes...and if that happens....watch its $6B market cap go down the drain! The suits on Wall Street won’t allow that to happen.

Don’t forget, the Patent holders / inventors of Exondys are on the ATL1102 Scientific Advisory Board

As patent holders no doubt they get royalty from Sarepta....you reckon Sue would be putting a few ‘what if?’ scenarios on whiteboard for ANP board re partnership?

If Exondys fails in the US, it will be a setback for everybody, most of all the DMD patients.

So many angles to this story.

How desperate is Sarepta?